# EDGAR Filing Document

**Accession Number:** 0001094038
**File Stem:** 0001104659-25-057836
**Filing Date:** 2025-6
**Character Count:** 6756
**Document Hash:** 2a69ffd95687b3ca4a5f3d0d80588eb9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-057836.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001104659-25-057836

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250606

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Marker Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001094038
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880277072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37939
- **FILM NUMBER:** 251034237

**BUSINESS ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** SUITE BCM-A, MS: BCM251
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021
- **BUSINESS PHONE:** (713) 400-6400

**MAIL ADDRESS:**
- **STREET 1:** 2450 HOLCOMBE BLVD
- **STREET 2:** SUITE BCM-A, MS: BCM251
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC.
- **DATE OF NAME CHANGE:** 20170629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC
- **DATE OF NAME CHANGE:** 20070628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENEMAX CORP
- **DATE OF NAME CHANGE:** 20020718

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**<u>FORM 8-K</u>**

**<u>CURRENT REPORT</u>**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

 **<u>June 6, 2025</u>**

Date of Report (Date of earliest event reported)

**<u>MARKER THERAPEUTICS, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>001-37939</u>** | **<u>45-4497941</u>** |
| (State or other jurisdiction of <br> incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **2450 Holcombe Blvd, Suite BCM-A, MS: BCM251**<br> **<u>Houston</u>** **<u>, Texas</u>** | **<u>77021</u>** |
| (Address of principal executive offices) | (Zip Code) |

---

**(713) 400-6400**

Registrant's telephone number, including area code

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | MRKR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2025. Of the 11,314,835 shares outstanding as of the record date, 7,629,048 shares, or 67.43%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

**Proposal No. 1**: Election of four nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes For** | **Votes<br> Withheld** | **Votes<br> Withheld** |
| David Eansor |  | 4095249 |  | 711872 |
| Steven Elms |  | 4094745 |  | 712376 |
| Katharine Knobil |  | 4079812 |  | 727309 |
| Juan Vera |  | 4143496 |  | 663625 |

---

Broker Non-Votes: 2,821,927.

All nominees were elected.

**Proposal No. 2**: Approval, on an advisory basis, of the compensation of the Company's named executive officers. The votes were cast as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes For** | **Votes<br> Against** | **Votes<br> Against** | **Abstained** | **Abstained** |
| Advisory approval of named executive officer compensation |  | 4449829 |  | 343434 |  | 13857 |

---

Broker Non-Votes: 2,821,927.

**Proposal No. 3**: Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes were cast as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes For** | **Votes<br> Against** | **Votes<br> Against** | **Abstained** | **Abstained** |
| Ratification of appointment of Marcum LLP |  | 7494386 |  | 80755 |  | 53907 |

---

Broker Non-Votes: 0.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Marker Therapeutics, Inc.** | **Marker Therapeutics, Inc.** |
| Dated: June 9, 2025 | By: | /s/ Juan Vera |
|  |  | Juan Vera |
|  |  | *President and Chief Executive Officer* |

---